Here are the S-1 registration statements from Curis Inc (CRIS) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
An S-1 covers the registration statement a company files to sell shares publicly, so if you follow CRIS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CRIS filings page.
Curis, Inc. is registering up to 3,731,344 shares of common stock, up to 3,731,344 pre-funded warrants, up to 3,731,344 August 2026 common warrants, and up to 7,462,688 shares issuable upon warrant exercise in a best-efforts offering. Securities are priced off an assumed combined offering price of $4.02 per common share and warrant, implying estimated net proceeds of about $13.6 million if the maximum number of common shares is sold. Curis intends to use proceeds primarily for research and development of its lead candidate emavusertib (CA-4948) and for working capital.
The company is a biotechnology developer of an oral IRAK4/FLT3 inhibitor in Phase 1/2 PCNSL and Phase 2 CLL combination trials, with Orphan Drug Designations in several indications and regulatory feedback supporting potential accelerated pathways. As of March 31, 2026, Curis had $15.0 million in cash and cash equivalents, a net loss of $24.2 million for the quarter, and an accumulated deficit of $1.3 billion. Curis states its current liquidity raises substantial doubt about its ability to continue as a going concern and that this offering alone will not resolve that doubt beyond 12 months. A 1-for-20 reverse stock split was effected on July 2, 2026.